← Library
Teriparatide
FDA ApprovedSince 2002
Also known as Forteo
Function
Primary
Osteoporosis
Mechanism
Recombinant PTH(1-34) — intermittent dosing preferentially stimulates osteoblast activity and bone formation.
Evidence
Clinical RCT (Phase III)
Research
Phase III Fracture Prevention Trial
Dosing
Range
20 mcg/day
Frequency
Daily
Route
Subcutaneous
Cycling
Maximum 2-year lifetime use.
Benefits
- ·Increased BMD at spine and hip
- ·Reduction in vertebral fractures
- ·Anabolic, not antiresorptive
Risks
- ·Osteosarcoma (black box, rodent)
- ·Hypercalcemia
- ·Orthostatic hypotension
- ·Leg cramps
Contraindications
- ·Prior skeletal radiation
- ·Paget's disease
- ·Pediatric/open epiphyses
- ·Hypercalcemia
Regulatory
FDA-Approved Rx
Functional Groups
Cited Works
- Neer RM et al. Effect of parathyroid hormone on fractures and bone mineral density (Fracture Prevention Trial). N Engl J Med. 2001;344:1434.source